Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid.

Kulkarni R, Payne AS, Werth VP, Sollecito TP, Stoopler ET.

Int J Dermatol. 2020 Jan 7. doi: 10.1111/ijd.14765. [Epub ahead of print] No abstract available.

PMID:
31909487
2.

Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.

Krain RL, Kushner CJ, Tarazi M, Gaffney RG, Yeguez AC, Zamalin DE, Pearson DR, Feng R, Payne AS, Werth VP.

Front Immunol. 2019 Nov 6;10:2571. doi: 10.3389/fimmu.2019.02571. eCollection 2019.

3.

Cutaneous lupus erythematosus induced by drugs - novel insights.

Borucki R, Werth VP.

Expert Rev Clin Pharmacol. 2020 Jan;13(1):35-42. doi: 10.1080/17512433.2020.1698290. Epub 2019 Dec 2.

PMID:
31774327
4.

Dermatomyositis in patients with autoimmune blistering diseases.

Patsatsi A, Pearson DR, Werth VP.

Int J Womens Dermatol. 2019 Jun 4;5(4):256-260. doi: 10.1016/j.ijwd.2019.05.009. eCollection 2019 Sep. Review.

5.

Potential allergenicity of commonly sold high SPF broad spectrum sunscreens in the United States; from the perspective of patients with autoimmune skin disease.

Keyes E, Werth VP, Brod B.

Int J Womens Dermatol. 2019 May 23;5(4):227-232. doi: 10.1016/j.ijwd.2019.05.006. eCollection 2019 Sep.

6.

Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.

Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS.

JAMA Dermatol. 2019 Oct 23. doi: 10.1001/jamadermatol.2019.3236. [Epub ahead of print]

PMID:
31642878
7.

10th Annual Meeting of the Rheumatologic Dermatology Society.

Sontheimer RD, Werth VP, Connolly MK.

Ann Transl Med. 2019 Aug;7(Suppl 4):S159. doi: 10.21037/atm.2019.08.66. No abstract available.

8.

Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.

Chen KL, Zeidi M, Werth VP.

Curr Rheumatol Rep. 2019 Aug 31;21(10):53. doi: 10.1007/s11926-019-0850-9. Review.

PMID:
31473845
9.

Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project.

Manzi S, Raymond S, Tse K, Peña Y, Anderson A, Arntsen K, Bae SC, Bruce I, Dörner T, Getz K, Hanrahan L, Kao A, Morand E, Rovin B, Schanberg LE, Von Feldt JM, Werth VP, Costenbader K.

Lupus Sci Med. 2019 Jul 19;6(1):e000342. doi: 10.1136/lupus-2019-000342. eCollection 2019.

10.

Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis.

Moshiri AS, Elenitsas R, Gaddis KJ, Werth VP, Nguyen CV, Pearson D, Rubin AI.

J Cutan Pathol. 2019 Jul;46(7):467-470. doi: 10.1111/cup.13409. No abstract available.

PMID:
31355484
11.

Cross-cultural adaptations of health-related quality of life measures.

Chakka S, Werth VP.

Br J Dermatol. 2019 Oct;181(4):659-660. doi: 10.1111/bjd.18272. Epub 2019 Jul 28. No abstract available.

PMID:
31353454
12.

A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach.

Jarrett P, Werth VP.

J Multidiscip Healthc. 2019 May 31;12:419-428. doi: 10.2147/JMDH.S179623. eCollection 2019. Review.

13.

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.

Ahmed S, Chakka S, Concha J, Krain R, Feng R, Werth VP.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18223. [Epub ahead of print]

PMID:
31206600
14.

Management of autoimmune blistering diseases in pregnancy and the neonate.

Krain RL, Chen KL, Werth VP.

G Ital Dermatol Venereol. 2019 Oct;154(5):539-549. doi: 10.23736/S0392-0488.19.06375-2. Epub 2019 Jun 12.

PMID:
31195784
15.

Understanding cutaneous lupus erythematosus: a step forward.

Albrecht J, Werth VP.

Br J Dermatol. 2019 Jun;180(6):1292-1293. doi: 10.1111/bjd.17911. No abstract available.

PMID:
31157430
16.

Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice.

Gandiga PC, Zhang J, Sangani S, Thomas P, Werth VP, George MD.

Br J Dermatol. 2019 Nov;181(5):1090-1092. doi: 10.1111/bjd.18133. Epub 2019 Aug 18. No abstract available.

PMID:
31102270
17.

Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study.

Pearson DR, Werth VP.

Front Med (Lausanne). 2019 Apr 24;6:85. doi: 10.3389/fmed.2019.00085. eCollection 2019.

18.
19.

Developing classification criteria for skin-predominant dermatomyositis: the Delphi process.

Concha JSS, Pena S, Gaffney RG, Patel B, Tarazi M, Kushner CJ, Merola JF, Fiorentino D, Dutz JP, Goodfield M, Nyberg F, Volc-Platzer B, Fujimoto M, Ang CC, Werth VP; Skin Myositis Delphi Group.

Br J Dermatol. 2019 May 3. doi: 10.1111/bjd.18096. [Epub ahead of print]

PMID:
31049930
20.
21.

Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?

Liu ML, Werth VP, Williams KJ.

Ann Rheum Dis. 2019 Apr 20. pii: annrheumdis-2019-215505. doi: 10.1136/annrheumdis-2019-215505. [Epub ahead of print] No abstract available.

PMID:
31005899
22.

Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.

Chen KL, Krain RL, Werth VP.

F1000Res. 2019 Mar 25;8. pii: F1000 Faculty Rev-332. doi: 10.12688/f1000research.17787.1. eCollection 2019. Review.

23.

Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials.

Tarazi M, Gaffney RG, Feng R, Werth VP.

Br J Dermatol. 2019 Oct;181(4):841-842. doi: 10.1111/bjd.17926. Epub 2019 Jul 24. No abstract available.

PMID:
30920654
24.

Relative risk of microscopic colitis in dermatomyositis.

Pearson DR, Werth VP.

J Am Acad Dermatol. 2019 Nov;81(5):1188-1190. doi: 10.1016/j.jaad.2019.03.045. Epub 2019 Mar 23. No abstract available.

PMID:
30910660
25.

Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus.

Gardet A, Pellerin A, McCarl CA, Diwanji R, Wang W, Donaldson D, Franchimont N, Werth VP, Rabah D.

Front Immunol. 2019 Feb 21;10:275. doi: 10.3389/fimmu.2019.00275. eCollection 2019.

26.

Practice-based differences in paediatric discoid lupus erythematosus.

Arkin LM, Buhr K, Brandling-Bennett H, Chiu Y, Chong B, Curran M, Hunt R, Paller AS, Werth VP, Klein-Gitelman M, von Scheven E, Ardalan K.

Br J Dermatol. 2019 Oct;181(4):805-810. doi: 10.1111/bjd.17780. Epub 2019 Jun 23.

PMID:
30768778
27.

Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis.

Gaffney RG, Feng R, Pearson DR, Tarazi M, Werth VP.

J Am Acad Dermatol. 2019 Jun;80(6):1793-1794. doi: 10.1016/j.jaad.2019.01.028. Epub 2019 Jan 24. No abstract available.

PMID:
30685266
28.

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N.

J Clin Invest. 2019 Mar 1;129(3):1359-1371. doi: 10.1172/JCI124466. Epub 2019 Feb 18.

29.

Supplementing Dermatology Physician Resident Education in Vasculitis and Autoimmune Connective Tissue Disease: A Prospective Study of an Online Curriculum.

Haemel A, Kahl L, Callen J, Werth VP, Fiorentino D, Fett N.

JAMA Dermatol. 2019 Mar 1;155(3):381-383. doi: 10.1001/jamadermatol.2018.4837. No abstract available.

30.

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.

Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, Illei G, Tummala R.

Lupus Sci Med. 2018 Nov 26;5(1):e000284. doi: 10.1136/lupus-2018-000284. eCollection 2018.

31.

Evaluating results of an interferon-γ release assay in patients with autoimmune disease who are taking hydroxychloroquine.

Gaffney RG, Werth VP.

J Am Acad Dermatol. 2019 Apr;80(4):1162-1164. doi: 10.1016/j.jaad.2018.12.027. Epub 2018 Dec 21. No abstract available.

PMID:
30582995
32.

Bullous pemphigoid in adolescence.

Patsatsi A, Kyriakou A, Werth VP.

Pediatr Dermatol. 2019 Mar;36(2):184-188. doi: 10.1111/pde.13717. Epub 2018 Dec 19. Review.

PMID:
30569520
33.

The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria.

Concha JSS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP.

Br J Dermatol. 2019 May;180(5):1001-1008. doi: 10.1111/bjd.17536. Epub 2019 Feb 25. Review.

PMID:
30561064
34.

Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference.

Lee J, Werth VP, Hall RP 3rd, Eming R, Fairley JA, Fajgenbaum DC, Harman KE, Jonkman MF, Korman NJ, Ludwig RJ, Murrell DF, Musette P, Naik HB, Sadik CD, Yamagami J, Yale ML, Payne AS.

Front Med (Lausanne). 2018 Nov 8;5:306. doi: 10.3389/fmed.2018.00306. eCollection 2018.

35.

Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus.

Kushner CJ, Concha JSS, Pearson DR, Werth VP.

Arthritis Rheumatol. 2019 Mar;71(3):478. doi: 10.1002/art.40779. Epub 2019 Feb 1. No abstract available.

PMID:
30427589
36.

Alopecias in lupus erythematosus.

Concha JSS, Werth VP.

Lupus Sci Med. 2018 Oct 25;5(1):e000291. doi: 10.1136/lupus-2018-000291. eCollection 2018.

37.

Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.

Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology.

J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. Review.

38.

Fatigue in systemic lupus erythematosus and other autoimmune skin diseases.

Tarazi M, Gaffney RG, Pearson D, Kushner CJ, Werth VP.

Br J Dermatol. 2019 Jun;180(6):1468-1472. doi: 10.1111/bjd.17257. Epub 2018 Nov 22.

PMID:
30269332
39.

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.

Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.

PMID:
30249507
40.

Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.

Concha JSS, Patsatsi A, Marshak-Rothstein A, Liu ML, Sinha AA, Lee LA, Merola JF, Jabbari A, Gudjonsson JE, Chasset F, Jarrett P, Chong B, Arkin L, Fernandez AP, Caproni M, Greenberg SA, Kim HJ, Pearson DR, Femia A, Vleugels RA, Fiorentino D, Fujimoto M, Wenzel J, Werth VP.

J Invest Dermatol. 2019 Feb;139(2):270-276. doi: 10.1016/j.jid.2018.08.017. Epub 2018 Sep 19. No abstract available.

PMID:
30243657
41.

Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.

Zeidi M, Kim HJ, Werth VP.

J Invest Dermatol. 2019 Feb;139(2):324-332. doi: 10.1016/j.jid.2018.07.041. Epub 2018 Sep 15.

PMID:
30227141
42.

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept.

Tarazi M, Aiempanakit K, Werth VP.

JAAD Case Rep. 2018 Aug 16;4(7):698-700. doi: 10.1016/j.jdcr.2018.03.008. eCollection 2018 Aug. No abstract available.

43.

Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings.

Zeidi M, Chansky PB, Werth VP.

J Am Acad Dermatol. 2019 Mar;80(3):801-804. doi: 10.1016/j.jaad.2018.08.019. Epub 2018 Aug 27. No abstract available.

PMID:
30165168
44.

Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study.

Samotij D, Szczęch J, Kushner CJ, Mowla MR, Dańczak-Pazdrowska A, Antiga E, Chasset F, Furukawa F, Hasegawa M, Hashizume H, Islam A, Ikeda T, Lesiak A, Polańska A, Misery L, Szepietowski JC, Tsuruta D, Adamski Z, Werth VP, Reich A.

Biomed Res Int. 2018 Jul 25;2018:3491798. doi: 10.1155/2018/3491798. eCollection 2018.

45.

Systemic sclerosis: Current concepts of skin and systemic manifestations.

Pearson DR, Werth VP, Pappas-Taffer L.

Clin Dermatol. 2018 Jul - Aug;36(4):459-474. doi: 10.1016/j.clindermatol.2018.04.004. Epub 2018 Apr 12. Review.

PMID:
30047430
46.

Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.

Kushner CJ, Tarazi M, Gaffney RG, Feng R, Ardalan K, Brandling-Bennett HA, Castelo-Soccio L, Chang JC, Chiu YE, Gmuca S, Hunt RD, Kahn PJ, Knight AM, Mehta J, Pearson DR, Treat JR, Wan J, Yeguez AC, Concha JSS, Patel B, Okawa J, Arkin LM, Werth VP.

Br J Dermatol. 2019 Jan;180(1):165-171. doi: 10.1111/bjd.17012. Epub 2018 Oct 5.

PMID:
30033560
47.

Drug-induced dermatomyositis after lacosamide: A case report.

Gaffney RG, Tarazi M, Werth VP.

JAAD Case Rep. 2018 Jun 13;4(6):584-585. doi: 10.1016/j.jdcr.2018.03.009. eCollection 2018 Jul. No abstract available.

48.

Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.

Ker KJ, Teske NM, Feng R, Chong BF, Werth VP.

J Am Acad Dermatol. 2018 Dec;79(6):1053-1060.e3. doi: 10.1016/j.jaad.2018.06.040. Epub 2018 Jun 30.

49.

Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis.

Cadena I, Werth VP, Levine P, Yang A, Downey A, Curtin J, Muggia F.

Ecancermedicalscience. 2018 May 22;12:837. doi: 10.3332/ecancer.2018.837. eCollection 2018.

50.

Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.

Samotij D, Szczęch J, Werth VP, Furukawa F, Kuhn A, Szepietowski JC, Reich A.

Postepy Dermatol Alergol. 2018 Apr;35(2):192-198. doi: 10.5114/ada.2018.75242. Epub 2018 Apr 24.

Supplemental Content

Loading ...
Support Center